Loading...

Iterum Therapeutics plc

ITRMF•PNK
Healthcare
Biotechnology
$0.02
$-0.00(-15.60%)
U.S. Market opens in 5h 48m

Iterum Therapeutics plc (ITRMF) Stock Overview

Explore Iterum Therapeutics plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap1.1M
P/E Ratio-0.02
EPS (TTM)$-0.72
ROE6.02%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

ITRMF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Iterum Therapeutics plc (ITRMF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.02 and a market capitalization of 1.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
20.00%
5-Day Change
265.85%
1-Month Change
-82.51%
3-Month Change
-91.18%
6-Month Change
-95.55%
Year-to-Date (YTD) Change
-91.04%
1-Year Change
-97.22%
3-Year Change
-97.50%
5-Year Change
-99.80%
All-Time (Max) Change
-99.98%

Contact Information

https://www.iterumtx.com
353 1 903 8354
3 Dublin Landings, Dublin, NaN, D01 C4E0

Company Facts

9 Employees
IPO DateMay 25, 2018
CountryIE
Actively Trading

Frequently Asked Questions